Abstract
CHIP (325 mg/M2), a second generation cisplatin derivative, was administered intravenously every 3 weeks to 85 pediatric patients with recurrent sarcomas (19), osteosarcomas (20), neuroblastoma (23), germ cell tumors (10), and other malignant tumors (7). Thirty-eight of them had been previously exposed to cisplatin. Partial remissions were only observed in 3 of 23 (13% SE=7%) patients having neuroblastoma. Severe thrombocytopenia (65%) and neutropenia (35%) were the dose limiting factors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Prestayko, Crooke S, Carter S: Cisplatin current status and new developments. Orlando, FL: Academic Press, 1980
Lenaz L, Canetta R, Hilgard P: The selection of new cisplatin analogues for clinical evaluation. Chemioterapia, 1:90–97, 1982
Kidami Y: Development of antitumor platinum complexes. Gan To Kagaku Ryoho, 10:2442–2452, 1983
Bocian E, Laverick and Nias AHW: The mode of action of cis-dichloro-bis (isopropylamine) trans dihydroxy platinum IV (CHIP) studied by the analysis of chromosome aberration production. B J Cancer, 47:503–509, 1983
Creaven PJ, Madajewicz S, Pendyala L, Mittelman A, Pontes E, Spaulding M, Arbuck S, Solomon J: Phase I clinical trial of cis-dichloro-transdihydroxy-bis-isopropylamine platinum (IV) (CHIP). Cancer Treat Rep, 67:795–800, 1983
Paolozzi FP, Gaver R, Poiesz BJ, Louie A, DiFino S, Comis RL, Newman N, Ginsberg S: Phase I-preliminary phase II trial of iproplatin, a cisplatinin analogue. Invest New Drugs, 6:199–206, 1988
Sessa C, Vermorken J, Renard J, Kaye S, Smith D, ten Bokkel Huinink W, Cavalli F, Pinedo H: Phase II study of iproplatin in advanced ovarian carcinoma. J Clin Oncol, 6:98–105, 1988
Pratt CB, Kamen BA, Winick N, Sartain P, Champion JE, Ragab AH, Goren MP: Phase I study of Iproplatin in pediatric patients: A Pediatric Oncology Group study. Cancer Treat Rep 71(1):87–88, 1987
Karnofsky DA, Burchenal JH: The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM (ed), Evaluation of Chemotherapeutic Agents Symposium, Microbiology Section, NY Academy of Medicine, New York, NY, 1948, New York: Columbia Press, 1949, 191–205
Castleberry R, Green A, Shuster J, Cantor A, Smith I, Joshi V: Up front phase II therapy with ifosfamide (IF), carboplatin (CBP), and iproplatin (IPP) in untreated children > 365 days of age with disseminated (POG stage D) neuroblastoma (NB). A Pediatric Oncology Group (POG) study. Med Pediatr Oncol, 18(5):383, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nitschke, R., Pratt, C., Harris, M. et al. Evaluation of CHIP (iproplatin) in recurrent pediatric malignant solid tumors. Invest New Drugs 10, 93–96 (1992). https://doi.org/10.1007/BF00873123
Issue Date:
DOI: https://doi.org/10.1007/BF00873123